Olivier Barraud

ORCID: 0000-0003-2015-9206

Also affiliated with Clinical Investigation Center Plurithematic Tours, Centre Hospitalier Universitaire de Limoges, Université de Limoges

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial”.

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

Critical Care(2022)10.1186/s13054-022-04204-9

N/A

2.1DataRank · unranked

94 citations

Bruno François, Marc Bourgeois, Apostolos Komnos, Ricard Ferrer, Galia Rahav +94 more

Microbiota-based markers predictive of development of Clostridioides difficile infection

Nature Communications(2021)10.1038/s41467-021-22302-0

N/A

0DataRank · unranked

89 citations

Mohamed Mysara, Basil Britto Xavier, Cornelis H. van Werkhoven, Pieter Monsieurs, Christine Lammens +52 more